Neuropace Inc at Morgan Stanley Global Healthcare Conference Transcript
All right, everyone. We can go ahead and get started. So welcome to another session at the Morgan Stanley Healthcare Conference. I'm Andrew Ranieri, one of the medical device analysts here. I'm delighted to have Michael Favet, CEO; and Rebecca Kuhn, CFO of NeuroPace. And before we just jump into it, I'd have to read our quick disclaimer. But for important disclosures, please see Morgan Stanley's research disclosure website morganstanley.com/researchdisclosures -- and if you have any questions, just reach out to your sales rep.
Questions & Answers
So with that, let's kind of kick it off. And Mike, maybe let's start on kind of the EMU volumes here. I mean, this has kind of been one of the ongoing debates and we've seen a lot of kind of fits and starts over Covid and maybe more recently in 2022 as we kind of moved into an endemic phase. So maybe just kind of give us an update on EMU volumes and if
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
